Vorinostat in Patients With Primary Cutaneous T-Cell Lymphoma

Phase 2

Terminated

Conditions: Cutaneous T-cell Lymphoma Stage IV
Cutaneous T-cell Lymphoma Stage II
Cutaneous T-cell Lymphoma Stage III
Cutaneous T-cell Lymphoma Stage I

Interventions: Drug: vorinostat
Other: flow cytometry
Other: laboratory biomarker analysis

Registration Number: NCT00958074

Lead Sponsor: University of Washington

Brief Summary: This phase II trial studies the side effects and how well vorinostat works in treating patients with primary cutaneous T-cell lymphoma. Vorinostat may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth

Detailed Description: PRIMARY OBJECTIVES:

I. To determine the objective response rate to treatment with dose-adjusted Vorinostat schedule in subjects with cutaneous T-cell lymphoma (CTCL) who did not receive prior systematic therapy or have been treated with single agent targretin (bexarotene).

SECONDARY OBJECTIVES:

I. To determine the safety and tolerability of dose-adjusted Vorinostat schedule when administered to patients with primary cutaneous T-cell lymphoma who did not receive prior systematic therapy or have been treated with single agent targretin.

II. To determine the time to objective response in subjects with CTCL treated with dose-adjusted schedule of Vorinostat as primary therapy.

III To determine the duration of objective response in subjects with CTCL.

IV. To determine the time to loss of objective response.

V. To determine the objective response rate of extracutaneous manifestations of CTCL (lymph node enlargement, Sezary cells in peripheral blood).

VI. To compare the efficacy, toxicity and tolerability of dose-adjusted schedule to currently recommended flat dose of Vorinostat in subjects with CTCL.

OUTLINE: Patients are assigned to 1 of 2 treatment arms according to age (\< 65 vs \>= 65 years old).

COHORT I (\>= 65 years old): Patients receive 200 mg vorinostat orally (PO) once daily (QD) on days 1-28. Treatment repeats every 28 days for 6 courses in the absence of disease progression or unacceptable toxicity.

COHORT II (\< 65 years old): Patients receive 400 mg vorinostat PO QD on days 1-28. Treatment repeats every 28 days for 6 courses in the absence of disease progression or unacceptable toxicity.

After completion of study treatment, patients are followed up for at least 30 days.

Recruitment & Eligibility

Status: TERMINATED

Sex: All

Target Recruitment: 11

Inclusion Criteria

Males or non-pregnant females
Histologically confirmed diagnosis of CTCL, including mycosis fungoides and/or Sezary syndrome
Documentation of diagnosis by histologic examination should be available
Subjects with CTCL stages IB, IIA, IIB, III, or IVA who have not received any prior systemic therapies
Anticipated life expectancy greater than 6 months
Performance status 0, 1, or 2 by Eastern Cooperative Oncology Group (ECOG) criteria
Written informed consent to participate in the study
Absolute neutrophil count (ANC) >= 1,000/mcL
Platelets >= 75,000/mcL
Hemoglobin >= 9 g/dL
Prothrombin time or international normalized ratio (INR) =< 1.5 x upper limit of normal (ULN) unless receiving therapeutic anticoagulation
Partial thromboplastin time (PTT) =< 1.2 times the ULN unless the patient is receiving therapeutic anticoagulation
Serum creatinine =< 1.5 X ULN OR calculated creatinine clearance >= 60 mL/min for patients with creatinine levels > 1.5 X institutional ULN; creatinine clearance should be calculated per institutional standard
Serum total bilirubin =< 2 X ULN
Aspartate aminotransferase (AST) (serum glutamic oxaloacetic aminotransaminase [SGOT]) and alanine aminotransferase (ALT) (serum glutamic pyruvic aminotransaminase [SGPT]) =< 3.0 X ULN
Alkaline Phosphatase (liver fraction) =< 3.0 X ULN

Exclusion Criteria

Proven or suspected extracutaneous visceral CTCL involvement (M1) (CTCL stage IVB)
Presence of lymphadenopathy is permitted
ECOG performance status > 2
Concomitant use of any anti-cancer therapy or immune modifier
Concomitant use of any investigational agent or device
Concomitant therapy with any other anti-CTCL therapy, or radiation therapy (topical corticosteroids or low dose oral corticosteroids [=< 10 mg/day prednisone or equivalent] will not be excluded, but if used, the dose and schedule must be stable during the two weeks immediately prior to study entry)
Use of any previous systemic therapy (except single agent targretin), total skin electron beam (TSEB) therapy or extracorporeal photopheresis
Evidence of clinically significant (uncontrolled) hypo- or hyperthyroidism
Poorly controlled diabetes mellitus as evidenced by hemoglobin (Hgb)A1c > 6.5 mg/dl
Recent (in the past 6 months) medically significant cardiac event (i.e. myocardial infarction, cardiac surgery)
Presence of congestive heart failure (New York Heart Association [NYHA] class IV) or angina (NYHA class IV) or presence of a medically significant arrhythmia
Congenital long QT syndrome
Corrected QT interval > 480 msec on screening electrocardiogram (ECG)
Presence of uncontrolled hypertension manifested by systolic blood pressure >= 180 mmHg and/or diastolic blood pressure >= 100 mmHg
Documented current active infection with human immunodeficiency virus (HIV), Hepatitis B, Hepatitis C, and/or cytomegalovirus (CMV)
Presence of uncontrolled bacterial or viral infection (subject may be receiving chronic antimicrobial therapy)
History of culture-documented bacteremia in the previous 2 weeks
Concurrent therapy with any histone deacetylase (HDAC)-like compound; patients treated with valproic acid for epilepsy may enroll after a 30 day washout period
Recent change (in the past 2 weeks) in the doses or regimens of medication used for any chronic non-oncologic conditions for reasons of worsening of chronic illness (change in doses of chronic medications associated with improvement in a chronic illness are not exclusion criteria)
Presence of any acute or chronic non-oncologic disease which, in the opinion of the investigator, is medically uncontrolled
History of a prior malignancy with the exception of cervical intraepithelial neoplasia; non-melanoma skin cancer; adequately treated localized prostate carcinoma with prostate specific antigen (PSA) < 1.0; or who has undergone potentially curative therapy with no evidence of that disease for five years, and/or who is deemed at low risk for recurrence (< 30% probability) by his/her treating physician
Patient with a "currently active" second malignancy, other than nonmelanoma skin cancer and carcinoma in situ of the cervix, should not be enrolled
Any significant medical or psychiatric condition that, in the opinion of the investigator, might prevent the subject from complying with all required study procedures
Women of childbearing potential must have a pregnancy test within 28 days prior to registration, and must use an adequate method of contraception to avoid pregnancy throughout the study and for a period of at least 3 months after the study
Females of childbearing potential and sexually active males, if indicated, must be willing and able to use two methods of contraception that are adequate to prevent or minimize risk of pregnancy for the duration of the study; one of which must be a barrier method
Patient has symptomatic ascites or pleural effusion (a patient who is clinically stable following treatment for these conditions is eligible)
Patient has had allogeneic transplant
Patient has a history of a gastrointestinal surgery or other procedures that might, in the opinion of the investigator, interfere with the absorption or swallowing of the study drugs

Study & Design

Study Type: INTERVENTIONAL

Study Design: PARALLEL

Arm && Interventions

Group	Intervention	Description
Cohort I (>=65 years old)	flow cytometry	200 mg vorinostat PO QD on days 1-28. Treatment repeats every 28 days for 6 courses. Dose escalation by 100mg per day increments to maximum dose of 500mg per day in the absence of dose limiting toxicity.
Cohort I (>=65 years old)	laboratory biomarker analysis	200 mg vorinostat PO QD on days 1-28. Treatment repeats every 28 days for 6 courses. Dose escalation by 100mg per day increments to maximum dose of 500mg per day in the absence of dose limiting toxicity.
Cohort II (<65 years old)	flow cytometry	400 mg vorinostat PO QD on days 1-28. Treatment repeats every 28 days for 6 courses. Dose escalation by 100mg per day increments to maximum dose of 500mg per day in the absence of dose limiting toxicity.
Cohort II (<65 years old)	laboratory biomarker analysis	400 mg vorinostat PO QD on days 1-28. Treatment repeats every 28 days for 6 courses. Dose escalation by 100mg per day increments to maximum dose of 500mg per day in the absence of dose limiting toxicity.
Cohort I (>=65 years old)	vorinostat	200 mg vorinostat PO QD on days 1-28. Treatment repeats every 28 days for 6 courses. Dose escalation by 100mg per day increments to maximum dose of 500mg per day in the absence of dose limiting toxicity.
Cohort II (<65 years old)	vorinostat	400 mg vorinostat PO QD on days 1-28. Treatment repeats every 28 days for 6 courses. Dose escalation by 100mg per day increments to maximum dose of 500mg per day in the absence of dose limiting toxicity.

Primary Outcome Measures

Name	Time	Method
Objective Response	After at least 14 days. With Confirmation after additional 28 days.	Defined as either no evidence of clinical disease or marked improvement (\>= 50%) decrease in the modified Severity-Weighted Assessment Tool (mSWAT) skin assessment score compared to baseline.

Secondary Outcome Measures

Name	Time	Method
Objective Response Rate of Extracutaneous Manifestations of CTCL (Lymph Node Enlargement, Sezary Cells in Peripheral Blood);	Up to 30 days post-treatment	Assessed by changes in the sum of the products in the greatest diameters of enlarged lymph nodes by serial computed tomography (CT) or positron emission tomography (PET)/CT scans.
Occurrences of Dose Adjustment as Measured by Safety/Toxicity	Up to 30 days post-treatment	Toxicities will be graded in severity according to the guidelines outlined in the National Cancer Institute-Common Terminology Criteria for Adverse Events (NCI-CTCAE) version 3.0.
Number of Participants With Overall Response as Measured by Sezary Cell Count	Baseline to 30 days post-treatment	Overall response defined by a clinically significant decrease in Sezary cell count (\>50% decrease from baseline).
Changes in the Physicians Serial Assessment of Erythroderma Score	Baseline to 30 days post-treatment